Company / Capital Expenditures
Cogent Biosciences, Inc. Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.6M
FY2025
5-year range
$573.0K / $6.9M
FY2021-FY2025
Trend
+171.2%
vs FY2024
Sector context
#101 of 195
Health Care
What the data says
At $2M, Cogent Biosciences, Inc.'s capital expenditures ranks #101 of 195 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $2M.
Based on SEC 10-K filings.
$2M in FY2025 with a 3-year CAGR of -39.0%.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -39.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#101 of 195 in Health CareTop 52% of 195This company $1.6M Sector average $116.9M
▼
-98.7% below sector average
Key checks
Key Insights
- 3-year CAGR of -39.0%, indicating a declining trend.
- In FY2025, capital expenditures increased 171.2% year-over-year.
- Ranks #101 out of 195 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6M | +171.2% |
| FY2024 | $573.0K | -79.5% |
| FY2023 | $2.8M | -59.3% |
| FY2022 | $6.9M | +299.2% |
| FY2021 | $1.7M | - |
| FY2020 | - | - |
| FY2019 | $33.0K | -94.0% |
| FY2018 | $549.0K | -39.8% |
| FY2017 | $912.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026